Back
Also listed as
HLBBF
OTC
Day Range
$4.82
$5.37
52-Week Range
$3.67
$6.41
Volume
1
50D / 200D Avg
$5.61
/
$5.13
Prev Close
$4.82
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 1.5 | 0.3 |
| P/B | 0.2 | 2.9 |
| ROE % | 12.8 | 3.7 |
| Net Margin % | 13.1 | 3.8 |
| Rev Growth 5Y % | 10.5 | 10.0 |
| D/E | 0.5 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
$0.00
$0.00 – $0.00
|
26 B | 0 |
| FY2026 |
$0.00
$0.00 – $0.00
|
25 B | 0 |
Key Takeaways
Revenue grew 10.50% annually over 5 years — strong growth
ROE of 12.78% — decent returns on equity
Debt/Equity of 0.48 — conservative balance sheet
Generating 4.33B in free cash flow
P/E of 1.50 — trading at a low valuation
Cash machine — converts 136.09% of earnings into free cash flow
Growth
Revenue Growth (5Y)
10.50%
Revenue (1Y)10.42%
Earnings (1Y)1.33%
FCF Growth (3Y)10.05%
Quality
Return on Equity
12.78%
ROIC12.87%
Net Margin13.11%
Op. Margin26.05%
Safety
Debt / Equity
0.48
Current Ratio1.44
Interest Coverage11.72
Valuation
P/E Ratio
1.50
P/B Ratio0.19
EV/EBITDA2.11
Dividend Yield0.03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.42% | Revenue Growth (3Y) | 10.46% |
| Earnings Growth (1Y) | 1.33% | Earnings Growth (3Y) | 17.93% |
| Revenue Growth (5Y) | 10.50% | Earnings Growth (5Y) | 24.68% |
| Profitability | |||
| Revenue (TTM) | 24.30B | Net Income (TTM) | 3.18B |
| ROE | 12.78% | ROA | 5.91% |
| Gross Margin | 79.58% | Operating Margin | 26.05% |
| Net Margin | 13.11% | Free Cash Flow (TTM) | 4.33B |
| ROIC | 12.87% | FCF Growth (3Y) | 10.05% |
| Safety | |||
| Debt / Equity | 0.48 | Current Ratio | 1.44 |
| Interest Coverage | 11.72 | Dividend Yield | 0.03% |
| Valuation | |||
| P/E Ratio | 1.50 | P/B Ratio | 0.19 |
| P/S Ratio | 0.20 | PEG Ratio | 8.40 |
| EV/EBITDA | 2.11 | Dividend Yield | 0.03% |
| Market Cap | 4.78B | Enterprise Value | 13.37B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 24.30B | 22.00B | 19.91B | 18.25B | 16.30B |
| Net Income | 3.18B | 3.14B | 2.29B | 1.92B | 1.32B |
| EPS (Diluted) | 3.21 | 3.17 | 2.31 | 1.93 | 1.33 |
| Gross Profit | 19.33B | 17.77B | 15.43B | 14.30B | 12.65B |
| Operating Income | 6.33B | 3.27B | 3.20B | 2.85B | 2.01B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 53.89B | 56.98B | 37.41B | 37.45B | 34.65B |
| Total Liabilities | 29.04B | 31.97B | 15.36B | 16.67B | 16.37B |
| Shareholders' Equity | 24.85B | 25.01B | 22.05B | 20.78B | 18.28B |
| Total Debt | 12.02B | 16.69B | 4.15B | 5.58B | 5.32B |
| Cash & Equivalents | 3.43B | 4.66B | 5.01B | 3.42B | 2.28B |
| Current Assets | 12.75B | 13.01B | 13.29B | 11.41B | 8.61B |
| Current Liabilities | 8.83B | 8.58B | 7.99B | 8.20B | 8.82B |
Strategy Scores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026